da Costa SCS, Bonadio RC, Gabrielli FCG, et al. - In this phase II trial, 107 individuals with locally advanced cervical cancer (LACC) were randomized to three cycles of neoadjuvant chemotherapy (NAC, n = 55) with cisplatin and gemcitabine followed by standard chemoradiation therapy (CRT, n = 52) with weekly cisplatin plus pelvic radiotherapy or to standard CRT alone in order to assess the efficiency and safety of NAC with cisplatin and gemcitabine followed by CRT. Results imply that for the treatment of LACC, adding NAC comprising of cisplatin and gemcitabine to standard CRT is not better and is probably inferior to CRT alone.